[Comparative evaluation of the reactogenicity and immunogenicity of inactivated influenza vaccines in the elderly]. / Sravnitel'noe izuchenie reaktogennosti i immunogennosti inaktivirovannykh grippoznykh vaktsin u lits pozhilogo vozrasta.

A comparative study was carried out to assess reactogenicity and immunogenicity of inactivated influenza vaccines (Begrivac, Vaxigrip, Grippol, Influvac, and Fluarix), licensed in Russia. Immunization of the elderly demonstrated low reactogenicity and high immunogenicity for all vaccines. Concomitant chronic diseases had no influence on the vaccine immunogenicity levels, which testifies to the benefit of vaccination in this age group. In the group of vaccinated the highest seroconversion to all vaccine strains was found for Vaxigrip (82-89% for group A viruses and 86% for group B virus); the vaccine demonstrated the highest level of diagnostic increase of antibody titers to all 3 viruses, i.e. 69.0% (p < .05), with 22.0% of vaccinees gained antibodies to 2 vaccine viruses (91.0% in total). The number of positive responses to 3 and 2 strains in subjects immunized with Fluarix, Begrivac and Influvac reached 85.0%, 85.0% and 83.0% respectively. It is noteworthy that the combination of surface antigens of A and B flu viruses in low concentration with polyoxidonium immune modulator in Grippol induced intensive immune response.

[The choice of the optimal schedules in the vaccination procedure against influenza in elderly subjects]. / Vybor optimal'nykh skhem v taktike vaktsinatsii protiv grippa pozhilykh liudei.

To improve the vaccinal prophylaxis of influenza, the comparative study of live trivalent influenza allantoic vaccine, dried, for adults, produced by the Irkutsk Enterprise for Immunological Preparations (Russia), and inactivated trivalent influenza split vaccine, obtained from Wyeth-Ayerst Company (USA), as well as schedules of their combined use for the vaccination of elderly persons, was carried out. The examination of 600 subjects revealed that the vaccines were well tolerated; the combined use of these two vaccines, as well as the use of the inactivated influenza vaccine (IIV) alone, ensured high immunogenic activity (60.0-80.0% of seroconversions). The live influenza vaccine (LIV) stimulated the production of specific antibodies only in 19.0-35.0% of the vaccinees; most of these vaccinees exhibited positive reaction only to one of the vaccine strains. Following the injection of LIV, the level of postvaccinal immunity was retained for at least 6 months. In the vaccinees receiving both vaccines the tendency towards a decrease in mean geometric titer values was less pronounced (0.2-0.4 log2) than in those receiving only IIV (0.5-0.7 log2). At the period of the rise of influenza morbidity, the contamination rate in the vaccinees with the positive postvaccinal dynamics of antibodies was low (26.0%). The indices of effectiveness were 3.8 for combined vaccination, 3.5 for IIV and 2.6 for LIV. The schedule of vaccination with IIV with the possible revaccination LIV 3-4 weeks later was recommended.